抑制MAT2A与癌症中的代谢和转录重编程作斗争
Fadi E Pulous1, Barbara Steurer1, Frank W Pun2
1Insilico Medicine US Inc, 1000 Massachusetts Avenue, Suite 126, Cambridge, MA 02138, USA.
Drug discovery today
|September 21, 2024
概括
向MAT2A (MET腺转移酶2α) 提供了一种新的抗瘤疗法. 它的抑制利用癌症的脆弱性,特别是在MTAP缺乏的瘤中,通过破坏代谢和转录过程.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症新陈代谢 癌症新陈代谢
背景情况:
- 致癌症包括代谢和转录的重编程,为向疗法创造脆弱性.
- MET腺转移酶2α (MAT2A) 调节细胞中的甲氨酸代谢和表观遗传转录.
- 异常的MAT2A功能通过代谢成,转录重新连接和免疫调节驱动恶性转变.
研究的目的:
- 审查MAT2A在癌症中的生物学作用.
- 概述目前MAT2A抑制剂的情况.
- 突出临床发展和MAT2A向治疗的机会.
主要方法:
- 关于MAT2A生物学及其在癌症中的作用的文献综述.
- 对当前MAT2A抑制剂药物开发的分析.
- 最近临床试验数据和治疗策略的摘要.
主要成果:
- MAT2A在维持MTAP缺乏的瘤中发挥着关键作用,呈现出合成致死性的脆弱性.
- 抑制MAT2A会影响瘤代谢,基因表达和瘤微环境 (TME).
- 几种MAT2A抑制剂正在临床前和临床开发中.
结论:
- 药物抑制MAT2A是一种有前途的治疗策略,可以对抗各种癌症,特别是那些有MTAP损失的癌症.
- 针对MAT2A提供了一种新的方法,通过利用代谢和表观遗传漏洞来对抗瘤生长.
相关概念视频
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
Master Transcription Regulators
6.9K
Master transcription regulators are regulatory proteins that are predominantly responsible for regulating the expression of multiple genes. Often these genes work in concert to drive a complex process. Activation of a master transcription regulator can lead to a cascade of transcriptional activation necessary for that outcome. These regulators can directly bind to the regulatory sequences of the various genes involved, or they can indirectly regulate transcription by binding to regulatory...
6.9K
Adaptive Mechanisms in Cancer Cells
5.7K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.7K
Epigenetic Regulation
3.0K
Epigenetic changes alter the physical structure of the DNA without changing the genetic sequence and often regulate whether genes are turned on or off. This regulation ensures that each cell produces only proteins necessary for its function. For example, proteins that promote bone growth are not produced in muscle cells. Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
X-chromosome...
X-chromosome...
3.0K
Electron Transport Chain: Complex I and II
12.2K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
12.2K


